Department of Oto-Rhino-Laryngology, Head and Neck Surgery, Ulm University Medical Center, 89075 Ulm, Germany.
Int J Mol Sci. 2020 May 31;21(11):3949. doi: 10.3390/ijms21113949.
Nuclear factor-κB (NF-κB) has been described as one of the most important molecules linking inflammation to cancer. More recently, it has become clear that NF-κB is also involved in the regulation of immune checkpoint expression. Therapeutic approaches targeting immune checkpoint molecules, enabling the immune system to initiate immune responses against tumor cells, constitute a key breakthrough in cancer treatment. This review discusses recent evidence for an association of NF-κB and immune checkpoint expression and examines the therapeutic potential of inhibitors targeting either NF-κB directly or molecules involved in NF-κB regulation in combination with immune checkpoint blockade.
核因子-κB（NF-κB）被描述为将炎症与癌症联系起来的最重要的分子之一。最近，人们越来越清楚地认识到 NF-κB 也参与了免疫检查点表达的调节。针对免疫检查点分子的治疗方法使免疫系统能够对肿瘤细胞发起免疫反应，这是癌症治疗的一个关键突破。本文综述了 NF-κB 与免疫检查点表达之间关联的最新证据，并探讨了直接针对 NF-κB 或与 NF-κB 调节相关的分子的抑制剂与免疫检查点阻断联合治疗的潜在治疗作用。
